Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has The Biomarker Clinical Phase Outsourcing Services Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_
In recent times, the biomarker clinical phase outsourcing services market has seen a remarkable rise in its size. The market growth predicted is from $9.71 billion in 2024 to a significant $11.91 billion in 2025, representing a compound annual growth rate (CAGR) of 22.7%. This surge in the past period has been due to a combination of factors such as increased efforts and funding from governments, enhancement in the use of biomarkers for diagnostics, a boost in R&D financial support from authorities, swift progress in technological fields like genomics, proteomics, and imaging, and a heightened requirement for cancer biomarkers._x000D_
_x000D_
In the next few years, the biomarker clinical phase outsourcing services market size is anticipated to witness significant expansion, increasing to a substantial$25.87 billion in 2029 at a compounded annual growth rate (CAGR) of 21.4%. This projected surge during the forecast period is primarily due to the escalating use of biomarkers in different stages of clinical trials, and the expanding application of biomarkers in these trials. Additionally, the increasing demand for precision and personalized medication, growing adoption of partner diagnostics, and the rise in the need for personalized medicine also contribute to this growth. Key trends to watch during the forecast period include the introduction of sophisticated parameters in the trials, diagnostics-centric clinical stages, swift advancements in biomarker technology, increased government initiatives and funding, and technological progress._x000D_
_x000D_
#Download a free sample to assess the report’s scope and structure:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp_x000D_
_x000D_
#What Are the Major Market Drivers Behind the Rising Adoption of Biomarker Clinical Phase Outsourcing Services Market?#_x000D_
The biomarker clinical phase outsourcing services market’s growth is anticipated to be driven by the increasing number of clinical trials. Clinical trials, which are research studies involving human participants to assess the safety and effectiveness of novel medical treatments, interventions, or diagnostic procedures, are on the rise. This upward trend is supported by advancements in medical research, an increasing incidence of chronic diseases, heightened investment from governmental and private entities, and a mounting demand for novel treatments and therapies. Outsourcing providers often possess specialist knowledge and experience in biomarker identification, validation, and analysis, which can improve the accuracy and trustworthiness of the biomarker data obtained during the trial. To illustrate, in May 2023, the United States National Library of Medicine stated that registered clinical trials had risen from 399,499 in 2022 to 437,533 across all 50 states and 221 countries. Additionally, it was reported that 140,492 studies (31%) are registered exclusively in the United States, while 241,498 studies (53%) are registered in locations outside of the U.S. Thus, the increase in clinical trials is anticipated to fuel the growth of the biomarker clinical phase outsourcing services market._x000D_
_x000D_
#Which Key Market Segments Comprise the Biomarker Clinical Phase Outsourcing Services Market and Drive Its Revenue Growth?#_x000D_
The biomarker clinical phase outsourcing servicesmarket covered in this report is segmented – _x000D_
_x000D_
1) By Type: Surrogate Endpoints; Predictive Biomarker; Prognostic Biomarker; Safety Biomarker; Other Biomarker Types_x000D_
2) By Service Type: Biomarker Validation; Biomarker Testing Services; Biomarker Sample Analysis_x000D_
3) By Therapeutic Area: Oncology; Neurology; Cardiology; Autoimmune Diseases; Other Therapeutic Areas_x000D_
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutions_x000D_
_x000D_
Subsegments:_x000D_
1) By Surrogate Endpoints: Tumor Marker-Based Endpoints; Imaging-Based Endpoints; Genetic or Genomic Markers _x000D_
2) By Predictive Biomarker: Genetic Predictive Biomarkers; Protein Predictive Biomarkers; Metabolomic Predictive Biomarkers _x000D_
3) By Prognostic Biomarker: Cancer Prognostic Biomarkers; Cardiovascular Prognostic Biomarkers; Neurological Prognostic Biomarkers _x000D_
4) By Safety Biomarker: Toxicity Biomarkers; Adverse Drug Reaction Biomarkers; Drug Interaction Biomarkers _x000D_
5) By Other Biomarker Types: Inflammation Biomarkers; Infectious Disease Biomarkers; Autoimmune Disease Biomarkers_x000D_
_x000D_
#Request customized data on this market:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp_x000D_
_x000D_
#Which Areas Are Leading Regions in the Biomarker Clinical Phase Outsourcing Services Market Expansion Across the Globe?#_x000D_
North America was the largest region in the biomarker clinical phase outsourcing services market in 2024. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_
_x000D_
#What Are the Strategic Trends Steering theBiomarker Clinical Phase Outsourcing Services Market Direction?#_x000D_
Major players in the biomarker clinical phase outsourcing services arena are concentrating on advancements in high-throughput flow cytometry and ELISpot testing to carve out a competitive advantage in the market. Both these technologies are used in the analysis of biomarkers and provide a fast and accurate evaluation of cellular markers and immune responses. As an illustration, Celerion Inc., a biotech outsourcing services firm based in the USA, broadened its service range to encompass GLP/GCP-compliant molecular and cell biology testing in November 2022. The strategic maneuver intends to boost Celerion’s ability to aid clients throughout the drug development lifecycle, from preliminary clinical research to regulatory filings. By incorporating GLP/GCP-compliant molecular and cell biology tests like pharmacokinetic (PK), pharmacodynamics (PD), and biomarker analysis, Celerion is able to offer a wider spectrum of services. This growth allows Celerion to support clients in generating high-caliber data that meet regulatory standards, thereby hastening the creation of new drugs._x000D_
_x000D_
#View the full report here:#_x000D_
_x000D_
#How Is the Biomarker Clinical Phase Outsourcing Services Market Conceptually Defined?#_x000D_
Biomarker clinical phase outsourcing services refer to the practice of contracting specialized firms or organizations to conduct various aspects of clinical trials related to biomarkers. Biomarkers are measurable indicators of biological states or conditions, often used in medical research and clinical trials to assess the effectiveness or safety of a drug or treatment._x000D_
_x000D_
#Purchase the full report and get a swift delivery:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15740_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Europe +44 7882 955267_x000D_
Asia & Others +44 7882 955267 & +91 8897263534_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model